The periodical about the pharmaceutical and medical equipment markets
(Russian pharmacies) - specialized periodical edition for pgarmacy professionals
Medical Council - Scientific Journal for Physicians
Home / News
Abbott officially launches new production line for anti-cancer drugs in Russia
The USA’s Abbott Laboratories (NYSE: ABT) has officially launched a new line for the production of anti-cancer drugs at the facilities of its Russian Veropharm subsidiary in the Belgorod region, reports The Pharma Letter’s local correspondent.
The new line was equipped and launched in accordance with Good Manufacturing Practice (GMP) standards and is part of a large-scale modernization program of the plant launched in 2016, with the total costs of more than 3 billion roubles ($48 million).
Under the terms of the project, the company will produce six anti-cancer drugs for the treatment of leukemia, and breast cancer, gastric, prostate and other cancers. Products from the plant will be appearing on the domestic market already at the beginning of next year.
In addition to the new line of anti-cancer drugs, modernization of the plant involves reconstruction of the plant, as well as the opening of at least two new product lines: for the production of hormonal preparations and nasal drops. It also involves reconstruction of a microbiology laboratory, along with the opening of a new research laboratory. In September 2016 the plant received GMP certificate from the Russian Ministry of Industry and Trade.
programmer of electronic software products